Anti-PD-L1 antibody atezolizumab is currently undergoing clinical trial for CLL patients in combination with anti-CD20 antibody obinutuzumab, and BCL-2 inhibitor venetoclax (14); however, final results are not yet reported. This evidence concerns the gene CD274 and B-cell chronic lymphocytic leukemia.